NCT00722839View on ClinicalTrials.gov

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Nonneoplastic Condition
Interventions
BIOLOGICAL

PADRE-CMV fusion peptide vaccine

Given subcutaneously

BIOLOGICAL

tetanus-CMV fusion peptide vaccine

Given subcutaneously

DRUG

agatolimod sodium

Given subcutaneously

Trial Locations (1)

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00722839 - Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants | Biotech Hunter | Biotech Hunter